<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">85263</article-id><article-id pub-id-type="doi">10.7554/eLife.85263</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Decoupled neoantigen cross-presentation by dendritic cells limits anti-tumor immunity against tumors with heterogeneous neoantigen expression</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-300799"><name><surname>Nguyen</surname><given-names>Kim Bich</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2269-6809</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-324627"><name><surname>Roerden</surname><given-names>Malte</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300865"><name><surname>Copeland</surname><given-names>Christopher J</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6882-3359</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300801"><name><surname>Backlund</surname><given-names>Coralie M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300802"><name><surname>Klop-Packel</surname><given-names>Nory G</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300863"><name><surname>Remba</surname><given-names>Tanaka</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300798"><name><surname>Kim</surname><given-names>Byungji</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8131-5255</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300803"><name><surname>Singh</surname><given-names>Nishant K</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-182264"><name><surname>Birnbaum</surname><given-names>Michael E</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2281-3518</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-17661"><name><surname>Irvine</surname><given-names>Darrell J</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-148045"><name><surname>Spranger</surname><given-names>Stefani</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3257-4546</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><institution content-type="dept">Koch Institute for Integrative Cancer Research</institution>, <institution>Massachusetts Institute of Technology</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Department of Biology</institution>, <institution>Massachusetts Institute of Technology</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-163045"><name><surname>Srivastava</surname><given-names>Pramod K</given-names></name><role>Reviewing editor</role><aff><institution>UConn Health</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>spranger@mit.edu</email> (SS);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>07</day><month>08</month><year>2023</year></pub-date><volume>12</volume><elocation-id>e85263</elocation-id><history><date date-type="received"><day>30</day><month>11</month><year>2022</year></date><date date-type="accepted"><day>06</day><month>08</month><year>2023</year></date></history><permissions><copyright-statement>Â© 2023, Nguyen et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Nguyen et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-85263-v1.pdf"/><abstract><p>Cancer immunotherapies, in particular checkpoint blockade immunotherapy (CBT), can induce control of cancer growth, with a fraction of patients experiencing durable responses. However, the majority of patients currently do not respond to CBT and the molecular determinants of resistance have not been fully elucidated. Mounting clinical evidence suggests that the clonal status of neoantigens (NeoAg) impacts the anti-tumor T cell response. High intratumor heterogeneity (ITH), where the majority of NeoAgs are expressed subclonally, is correlated with poor clinical response to CBT and poor infiltration with tumor-reactive T cells. However, the mechanism by which ITH blunts tumor-reactive T cells is unclear. We developed a transplantable murine lung cancer model to characterize the immune response against a defined set of NeoAgs expressed either clonally or subclonally to model low or high ITH, respectively. Here we show that clonal expression of a weakly immunogenic NeoAg with a relatively strong NeoAg increased the immunogenicity of tumors with low but not high ITH. Mechanistically we determined that clonal NeoAg expression allowed cross-presenting dendritic cells to acquire and present both NeoAgs. Dual NeoAg presentation by dendritic cells was associated with a more mature DC phenotype and a higher stimulatory capacity. These data suggest that clonal NeoAg expression can induce more potent anti-tumor responses due to more stimulatory dendritic cell : T cell interactions. Therapeutic vaccination targeting subclonally expressed NeoAgs could be used to boost anti-tumor T cell responses.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005190</institution-id><institution>Melanoma Research Alliance</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Spranger</surname><given-names>Stefani</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007038</institution-id><institution>Lung Cancer Research Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Spranger</surname><given-names>Stefani</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Michael E Birnbaum, is an equity holder in 3T Biosciences, and is a co-founder, equity holder, and consultant of Kelonia Therapeutics and Abata Therapeutics..</p></fn><fn fn-type="conflict" id="conf3"><p>Stefani Spranger, is a SAB member for Related Sciences,Arcus Biosciences, Ankyra Therapeutics and Venn Therapeutics. S.S. is a co-founder ofDanger Bio. S.S. is a consultant for TAKEDA, Merck, Tango Therapeutics, Dragonfly andRibon Therapeutics and receives funding for unrelated projects from Leap Therapeutics..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All experimental animal procedures were approved by the Committee on Animal Care (CAC/IACUC) at MIT.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All raw data are uploaded as source data files.</p></sec><supplementary-material><ext-link xlink:href="elife-85263-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>